Menin Inhibitors
2 drugsAbout Menin
Menin, encoded by the *MEN1* gene, is a protein target in oncology. Its precise mechanisms of action are still being investigated, but its importance in cancer biology is increasingly recognized.
While there is currently no genetic evidence data available linking *MEN1* mutations to specific diseases, the approval of Menin-targeting drugs underscores its therapeutic potential in oncology.
Menin is targeted by two FDA-approved small molecule drugs, REVUFORJ (SYNDAX) and KOMZIFTI (KURA), both indicated for oncology. REVUFORJ was the first approved in 2024, followed by KOMZIFTI in 2025.
Top Menin Drugs
The competitive landscape consists of SYNDAX and KURA, each with an approved Menin-targeting drug.
The presence of only two companies suggests a relatively open market with potential for new entrants.
Menin Drug Modality Landscape
Modalities
Routes of Administration
Menin is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like PROTACs or antibodies could provide a competitive advantage.
Menin Clinical Trials 42 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Menin. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 29 | 2 | 3 | 24 | 40% |
| Phase 2 | 8 | 0 | 0 | 8 | - |
| Phase 3 | 4 | 1 | 0 | 3 | 100% |
| Phase 4 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Menin Drug Approval Timeline (2024 - 2025)
The first Menin-targeting drug was approved in 2024, with the most recent approval in 2025.
The recent approvals suggest growing interest and investment in Menin as a therapeutic target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 22 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Menin. A trial counts if an approved drug acting on Menin is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.